Latest News - Earnings & Financials

Friday, March 10, 2017 | Earnings & Financials

Federal Insider Trading Trial Begins for Ex-Angel Player Doug DeCinces

An ex-Angel star who made more than a $1 million in investments related to a friend’s medical-device company appeared in federal court Thursday for the start of his insider-trading trial. A fede…

Read the full story

Wednesday, March 08, 2017 | Earnings & Financials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Provides Update on Products in Development

As part of its fourth quarter and full-year earnings results reporting, Aerie Pharmaceuticals provided updates on several of its products in clinical development, including: Rhopressa (netarsud…

Read the full story

Monday, February 20, 2017 | Earnings & Financials

Essilor to Launch Next Gen Varilux Lens Based on Fresh Approach to Product Development

Essilor is abandoning traditional methods of developing and designing products in favor of an innovative, customer-driven approach that has already yielded a new generation of Varilux progressive lens…

Read the full story

Friday, February 17, 2017 | Dry Eye, Earnings & Financials, Shire

Shire Provides Update on Early Xiidra Sales

As part of its fourth quarter and full-year earnings release on Thursday, Shire provided information about the early sales of its dry eye disease drug Xiidra (lifitegrast), which was launched in Augus…

Read the full story

Tuesday, February 14, 2017 | Earnings & Financials, Retina, Pixium Vision

Pixium Vision Receives NUB Innovation Reimbursement Status-1 for 150 Electrode IRIS II Bionic System in Germany

Pixium Vision announced that the German Institute for the Hospital Remuneration System (InEK) has granted NUB (Neue Untersuchungs- und Behandlungsmethoden) Status-1 for IRIS II, Pixium Vision’s …

Read the full story

Tuesday, February 14, 2017 | Earnings & Financials

Teva Said to Consider Options for Branded Generics Unit

Israeli drugmaker Teva Pharmaceutical Industries is weighing options including a sale of its branded generics products business as it works to reduce debt, according to people familiar with the m…

Read the full story

Monday, February 13, 2017 | Earnings & Financials, Bausch+Lomb

Bausch + Lomb Ends Unilateral Pricing Policy

Bausch + Lomb became the latest contact lens company to move away from its Unilateral Pricing Policy (UPP) with the announcement late Friday that a “competitive imbalance” had forced the c…

Read the full story

Friday, February 10, 2017 | Earnings & Financials, Regeneron Pharmaceuticals

Regeneron Forecasts 2017 US Eylea Sales Growth Below Estimates

Regeneron Pharmaceuticals forecast 2017 U.S. sales growth for its flagship eye drug Eylea that fell short of analysts' estimates, pushing its shares down 2.3 percent in premarket trading. The U.S.…

Read the full story

Monday, February 06, 2017 | Earnings & Financials, Alimera Sciences

Alimera Sciences Announces the Reimbursement of Iluvien in Italy

Alimera Sciences announced that it has received the pricing and reimbursement decree for Iluvien from Agenzia Italiana del Farmaco (AIFA) on January 11, 2017. The decree, published February 2, 2017, i…

Read the full story

Tuesday, January 31, 2017 | Earnings & Financials, Rayner Intraocular Lenses

Phoenix Equity Partners announces investment in Rayner Surgical Group

Phoenix Equity Partners announced an investment in Rayner Surgical Group alongside the current management team, led by Chief Execuive Officer Tim Clover, and a number of the company’s existing s…

Read the full story

Wednesday, January 25, 2017 | Earnings & Financials, Alcon, Novartis

Novartis Considers Spinning Off Alcon Unit

Novartis said it is considering several options for its Alcon unit, including the possibility of separating from the eye care division. The announcement comes after Novartis reported that Alcon’…

Read the full story

Monday, January 09, 2017 | Earnings & Financials, Ivantis

Ivantis Raises $25 Million Series C to Fund Future US Commercialization of the Hydrus Microstent for Minimally Invasive Glaucoma Surgery

Ivantis announced that it closed a $25 million Series C financing to support US commercialization of the Hydrus Microstent upon its anticipated 2018 FDA approval. The round was led by new investor RA …

Read the full story

Friday, January 06, 2017 | Earnings & Financials

Guardion Health Sciences Completes Registration with SEC, Becomes a Public Reporting Company

On December 27, 2016, the U.S Securities and Exchange Commission declared effective the Registration Statement on Form S-1 (No. 333-209488) of Guardion Health Sciences, making Guardion is a public rep…

Read the full story

Thursday, November 10, 2016 | Earnings & Financials, ReVision Optics

ReVision Optics Raises $32 Million to Fund Expansion of US Commercialization of Raindrop Near Vision Inlay

ReVision Optics announced that it has raised $32 million in an equity financing to support expansion of US commercialization of the company’s Raindrop Near Vision Inlay for the surgical correcti…

Read the full story

Tuesday, November 08, 2016 | Earnings & Financials, Valeant

Valeant Shares Plunge as It Slashes Guidance Again

Valeant Pharmaceuticals International Inc. cut its annual outlook again Tuesday as the drug company, struggling to remake its business after a series of missteps, signaled its turnaround may take long…

Read the full story
Load More